Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Explore this paper's citation graph
Summary
This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy, and proposes hyperprogressive disease, an acceleration of tumor growth following anti- PD-1 and PD-L 1 therapy, as a new response pattern associated with deleterious prognosis.
- Type
- review
- Published
- 2020-02-01
- Cited by
- 30
- References
- 78
- Access
- Open access
- OpenAlex
- https://openalex.org/W3005834155
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:211567802
Keywords
Medicine, Discontinuation, Combination therapy, Adverse effect, Immune system
References
- Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity
- Molecular and cellular insights into T cell exhaustion
- Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes
- Oncology meets immunology: the cancer-immunity cycle.
- Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
- Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
- CD8 + T cells in Autoimmunity
- IL-17 and Th17 Cells.
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Regulatory T cells exert checks and balances on self tolerance and autoimmunity
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- TH-17 cells in the circle of immunity and autoimmunity
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- The “cancer immunogram”
- Targeting T Cell Co-receptors for Cancer Therapy.
- Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4
Cited by
- Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
- Immune metabolism in PD-1 blockade-based cancer immunotherapy
- Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report
- Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
- Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer
- Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade
- Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
- Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
- PD-1 inhibition in advanced myeloproliferative neoplasms
- An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
- Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
- Expression of immune checkpoints on peripheral blood cells in patients with prostate cancer
- Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
- Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
- Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
- Recent advances in cellular immunotherapy for lymphoid malignancies
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
- Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study
- Tumor lysis syndrome in a patient with advanced lung squamous cell carcinoma undergoing combined therapy with a programmed cell death protein 1 inhibitor and first‑line chemotherapy: A case report
- Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens
Related papers
- Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
- A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade.
- Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- Tumor organoid-originated biomarkers predict immune response to PD-1 blockade.
- A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report
- Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma
- Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation
- Research advances in radiotherapy combined with immune checkpoint blockade
- Immune checkpoint blockade in CNS tumors